Jessica Jensen
Directeur Technique/Scientifique/R&D chez POINT Biopharma, Inc. (United States)
Postes actifs de Jessica Jensen
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
POINT Biopharma, Inc. (United States)
 POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million. | Directeur Technique/Scientifique/R&D | 01/08/2020 | - |
Historique de carrière de Jessica Jensen
Anciens postes connus de Jessica Jensen
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| POIT BIOP | Directeur Technique/Scientifique/R&D | 30/06/2021 | 27/12/2023 |
| PROGENICS PHARMACEUTICALS, INC. | Directeur Technique/Scientifique/R&D | 01/02/2018 | 01/08/2020 |
Formation de Jessica Jensen
| George Washington University | Graduate Degree |
| St. Joseph's University | Undergraduate Degree |
Statistiques
Internationale
| Etats-Unis | 6 |
Opérationnelle
| Chief Tech/Sci/R&D Officer | 3 |
| Graduate Degree | 1 |
| Undergraduate Degree | 1 |
Sectorielle
| Health Technology | 3 |
| Consumer Services | 3 |
| Commercial Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| POIT BIOP | Health Technology |
| Entreprise privées | 2 |
|---|---|
Progenics Pharmaceuticals, Inc.
 Progenics Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Progenics Pharmaceuticals, Inc. engages in the development of medicines and other products for targeting and treating cancer. Its pipeline includes therapeutic agents, imaging agents for prostate cancer, and imaging analysis technology. The company was founded by Paul J. Maddon on December 1, 1986 and is headquartered in New York, NY. | Health Technology |
POINT Biopharma, Inc. (United States)
POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million. | Commercial Services |
- Bourse
- Insiders
- Jessica Jensen
- Expérience
